BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Genzyme  B.V.,  the  Netherlands  submitted  on  30  June  1998  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Renagel,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  22-24  September 
1997,  this  medicinal  product  is  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No.  (EC) 
2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were as follows: 
Rapporteur:  
Dr. M. Toivonen 
Co-Rapporteur:  
Dr. D. Brasseur 
Licensing status: 
A New Drug Application was filed in the United States of America in October 1997 and approved in 
October 1998. A New Drug Application filed in Israel was approved in September 1999. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 24 July 1998. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 30 September 
1998. 
The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 7 October 
1998. 
During  its  meeting  on  17-19  November  1998,  the  CPMP  agreed  on  the  consolidated  list  of 
questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the 
company on 19 November 1998. 
The company submitted the responses to the consolidated list of questions on 10 June 1999. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  the  joint  response  assessment  report  on  the 
company’s responses to the list of questions to all CPMP Members on 16 August 1999.  
The company submitted supplementary information on 10 September 1999.   
On  13  September  1999,  the  CPMP  adopted  a  list  of  outstanding  pharmaceutical  and  clinical 
issues to be addressed by the company in writing and in an oral explanation. 
The  Rapporteur  and  the  Co-Rapporteur  circulated  a  further  joint  response  assessment  report, 
taking into account the company’s responses on the outstanding issues, to all CPMP Members 
on 17 September 1999. 
A  hearing  was  held  at  the  CPMP  meeting  on  21  September  1999,  to  address  the  remaining 
outstanding clinical issues.  
The CPMP, during their meeting on 21-23 September 1999, considered the responses provided 
by the company and discussed the recommendations presented by the Rapporteur. Amendments 
were discussed to the Summary of Product Characteristics and Package Leaflet texts. 
During  the  meeting  on  21-23  September  1999  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  by 
consensus for granting a Marketing Authorisation for Renagel under exceptional circumstances 
on 23 September 1999. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 28 January 2000. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
